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Abstract 
Background: Chloroquine has been administered to the soldiers of the Republic of Korea as prophylaxis against 
vivax malaria. Recent increase in the number of chloroquine‑resistant parasites has raised concern over the chemo‑
prophylaxis and treatment of vivax malaria.
Methods: To monitor the development of chloroquine‑resistant parasites in the Republic of Korea, analyses of single 
nucleotide polymorphisms (SNPs) of pvmdr1 and microsatellite markers were performed using samples collected 
from 55 South Korean soldiers infected with Plasmodium vivax.
Results: Four SNPs, F1076L, T529, E1233, and S1358, were identified. Among these, S1358 was detected for the first 
time in Korea. The microsatellite‑based study revealed higher genetic diversity in samples collected in 2012 than in 
2011.
Conclusions: Taken together, the results indicate that P. vivax with a newly identified SNP of pvmdr1 has been 
introduced into the Korean P. vivax population. Therefore, continuous monitoring for chloroquine‑resistant parasites is 
required for controlling vivax malaria in the Republic of Korea.
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Background
Malaria caused by Plasmodium vivax is the most com-
mon human malaria infection, affecting 40  % of the 
world’s population [1, 2]. In the Republic of Korea, 
vivax malaria had been successfully eliminated by the 
late 1970s by an effective World Health Organization 
(WHO) programme. However, this infectious disease has 
re-emerged, since a soldier was diagnosed with P. vivax 
infection in 1993 [3, 4]. Since then, vivax malaria has 
been the only type of malaria detected in the Republic of 
Korea, accounting for 18,052 cases reported from 1994 to 
2013 [5].
Vivax malaria endemic regions in the Republic of 
Korea are concentrated near the demilitarized zone that 
separates South Korea from the Democratic People’s 
Republic of Korea (DPRK or North Korea). Thus, mili-
tary personnel and residents living in the demilitarized 
zone are under high risk of contracting vivax malaria. 
Military personnel accounted for 25.3  % (1029/4063) 
of all malaria cases reported from 2008 to 2010 [6]. 
This percentage rose to 44.7  % (1811/4063) when mili-
tary personnel diagnosed with vivax malaria follow-
ing discharge from the service were counted [7]. In this 
regard, mass chemoprophylaxis using chloroquine and 
primaquine has been administered to soldiers since the 
year 1997 to control vivax malaria infection. For the 
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chemoprophylaxis, 300 mg chloroquine is administrated 
weekly to military personnel from June to August (for 
12 weeks), and then, 30 mg primaquine is administrated 
daily for 2 weeks.
Chloroquine has been used to not only kill P. vivax in 
asexual blood stages and gametocytes, but also to pre-
vent the spread of malaria in low-risk areas. However, its 
massive use in the treatment of vivax malaria and con-
tinuing long-term chemoprophylaxis could facilitate the 
acquisition of resistance to chloroquine [8]. Since the 
first report of chloroquine-resistant P. vivax in 1989 in 
Papua New Guinea, the number of chloroquine-resist-
ant cases has increased in several countries, including 
Indonesia, Southeast Asia, India, and Central and South 
America [9–15]. Although cases of chloroquine-resist-
ant malaria infections have been confirmed recently, 
chloroquine is still used as the therapeutic and chemo-
prophylactic drug for P. vivax infections in the Republic 
of Korea [16]. Thus, the administration of chloroquine to 
soldiers stationed near the demilitarized zone has raised 
the concern of accelerating the development of drug-
resistant P. vivax.
Monitoring the genetic polymorphism that con-
fers chloroquine resistance to malaria provides useful 
information regarding the efficacy of drugs in treating 
malaria. However, compared to P. falciparum, previous 
studies using genetic markers for chloroquine-resistant P. 
vivax did not conclude a strong correlation between the 
genetic markers and chloroquine-resistant phenotype in 
P. vivax, because the molecular mechanisms of chloro-
quine resistance in P. vivax is still elusive [17]. Among 
the genetic markers for chloroquine-resistant P. vivax, 
the multidrug resistance-1 gene of P. vivax (pvmdr1) 
has been identified as a possible genetic marker of chlo-
roquine resistance with in vitro characterization of iso-
lates [18]. In Southeast Asia and Papua New Guinea, 
the Y976F mutation (TAC→TTC) in pvmdr1 has been 
shown to be correlated with chloroquine resistance [19–
21]. In addition, the association of severe malaria and 
expression levels of pvmdr1 with chloroquine resistance 
was reported by showing 2.4-fold increase in pvmdr1 
expression levels in parasites from patients compared to 
the susceptible group of vivax malaria in the Brazilian 
Amazon [21]. This chloroquine resistance appears to be 
the result of a two-step mutation pathway, in which the 
F1076L mutation is followed by the Y976F mutation [22, 
23]. The F1076L mutation is found in all Korean samples 
tested, and is unlikely to result in chloroquine treatment 
failure [24], while the Y976F mutation has not yet been 
reported in the Republic of Korea [25]. However, con-
sidering that the South Korean military has been per-
forming mass chemoprophylaxis for more than 15 years, 
there likely is strong evolutionary pressure for selection 
of the double mutant.
Recently, the genetic diversity as well as intra- and 
inter-population relationships of P. vivax isolates 
obtained from the Republic of Korea (from 1994 to 2008) 
were analysed [26, 27]. By using microsatellite mark-
ers, this analysis provided an explanation for the genetic 
diversity observed among strains. In this study, the prev-
alence of five common non-synonymous single-nucleo-
tide polymorphisms (SNPs) and four synonymous SNPs 
at the pvmdr1 locus, including the Y976F and F1076L, 
was examined in 55 P. vivax isolates obtained from mili-
tary vivax malaria patients who had taken chemopro-
phylaxis near the demilitarized zone of the Republic of 
Korea. The population structure of these isolates was 




This study was approved by the ethics committee of the 
Army Forces Medical Command (Approval No. AFMC-
13-IRB-053, July 2011). An approval form was used to 
obtain written informed consent from each participant 
and all participants provided their informed consent for 
collecting a 5-mL blood sample.
Blood samples and DNA extraction
A total of 55 blood samples were collected from patients 
infected with malaria and admitted to the Armed Forces 
Hospitals near the demilitarized zone located in north-
ern Gyeonggi-do Province in the northwest region of the 
Fig. 1 Map of Gyeonggi‑do Province in the Republic of Korea: 
endemic regions of vivax malaria near the demilitarized zone in 
which samples were collected
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Republic of Korea in 2011 and 2012 (Fig. 1). The admis-
sion and clinical management of the patients were under-
taken independently of this study. Aliquots (200 μL) of 
venous blood samples were stored at −20  °C in ethyl-
enediaminetetraacetic acid (EDTA)-coated bottles until 
extracting genomic DNA using a QIAamp® DNA Blood 
Mini Kit (Qiagen, USA) according to the manufacturer’s 
instructions.
Identification of single nucleotide polymorphism (SNP) 
in the pvmdr1 gene
The pvmdr1 gene was amplified by nested PCR using 
pvmdr1 gene specific primers [25, 28]. Amplification 
of pvmdr1 gene fragments was performed applying a 
nested PCR approach and regents, primers, and cycling 
conditions as outlined in Table  1. The final PCR prod-
ucts were resolved by electrophoresis on a 1.5 % agarose 
gel stained with ethidium bromide, and visualized under 
ultraviolet illumination. The second PCR products were 
sequenced and the deduced amino acid sequences were 
compared to the amino acid sequence of pvmdr1 from 
the Sal I strain of P. vivax (Salvador I, GenBank acces-
sion no. AY571984). The amino acid sequence align-
ment and analyses were performed using Clustal Omega 
[29].
Analysis of ten microsatellite markers
To determine the relationships between the differ-
ent pvmdr1 genotypes of P. vivax, 10 microsatellite 
markers were typed for 28 samples collected in the 
year 2011 and 27 collected in the year 2012. The 
10 microsatellite markers used for this assay were 
as follows: MS1, MS3, MS5, MS8, MS10, MS12, 
MS16, MS20, Msp1F7, and Pv3,27. The primer sets 
and amplification conditions used for the PCRs 
have been described elsewhere [30, 31]. The fluo-
rophore-labelled PCR products were quantified 
using an Applied Biosystems 3730 DNA Analyzer 
with the GeneMapper software Version 4.0 (Applied 
Biosystems, USA). In order to reduce potential arti-
facts from background noise or stutter, an arbitrary 
fluorescent intensity threshold of 50 relative flores-
cence units was applied for peak detection. All elec-
tropherogram traces were additionally inspected 
manually. For each isolate, at each locus, the pre-
dominant allele, the highest intensity peak and any 
additional alleles with a peak height of at least one-
third of the height of the predominant allele were 
scored [32]. Genotyping success was defined as the 
presence of at least one allele at a given locus in a 
given sample.
Population genetic analyses and statistical treatments
The major alleles of each locus were used for our pop-
ulation genetic analysis. The level of genetic diversity 
of the P. vivax population in Republic of Korea was 
assessed by allele number per locus (A) and expected 
heterozygosity (He). The He values for each locus 
were calculated using the formula He  =  [n/(n  −  1)] 
[1 − ∑pi2], where n is the number of isolates examined 
and pi is the frequency of the ith allele. The statistical 
significance of the differences in these values was evalu-
ated by Welch’s t test.
Multilocus linkage disequilibrium (LD) was assessed 
using LIAN v3.6 based on the allelic data for the 10 
microsatellite DNA loci [33]. This program computed 
the standardized index of association (IAS), a measure of 
genotype-wide linkage. The P-values were determined by 
a Monte Carlo simulation process, performing 100,000 
iterations. Only those samples for which a complete set 
of microsatellite alleles were scored were used for this 
analysis. Additionally, the multilocus genotypes found in 
multiple isolates were only counted once in the analysis 
[34].
Microsatellite genotypes of the isolates were deter-
mined based on a combination of the allelic data of the 10 
loci. The relationships between the genotypes were deter-
mined by eBURST analysis [35].
Table 1 Primers and cycling condition of a nested PCR for amplifying pvmdr1
Primer name Sequence (5′–3′) Annealing temperature (°C) Size of PCR product (bp)
First pvmdr1 F1 TTGAACAAGAAGGGGACGTT 61 4290
pvmdr1 R1 CTTATATACGCCGTCCTGCAC
Second pvmdr1 F2 CAGCCTGAAAGATTTAGAAGCCTT 58 539
pvmdr1 R2 CATCCACGTCCACAGTGGAAC
pvmdr1 F3 GGATAGTCATGCCCCAGGATTG 62 604
pvmdr1 R3 CATCAACTTCCCGGCGTAGC
pvmdr1 F7 GATGAGCCTGCTGATGCGATTCTAC 60 745
pvmdr1 R5 ATATACGCCGTCCTGCACCGAG
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Results and discussion
In the Republic of Korea, an extensive malaria chemopro-
phylaxis campaign using chloroquine and primaquine has 
been conducted annually since the year 1997. The cumu-
lative numbers of the soldiers receiving this treatment 
exceeded approximately 1.8 million by 2011. Although 
this chemoprophylaxis has contributed to the contain-
ment of vivax malaria, the possibility of the emergence of 
chloroquine-resistant P. vivax strains has been a concern. 
Indeed, chemoprophylaxis failure has been reported in 
several cases, despite the attainment of sufficiently high 
plasma concentrations of hydroxychloroquine [6, 16]. 
Therefore, monitoring for chloroquine-resistant P. vivax 
is important for the control of malaria in Republic of 
Korea.
In vitro assays provide drug susceptibility estimates 
free from the effects of most factors that affect in  vivo 
assays. However, the lack of a robust, standardized and 
widely applicable protocol for long-term in vitro culture 
hinders P. vivax malaria research. Therefore, short-term 
ex  vivo assays have been successfully used to moni-
tor the chloroquine resistance of P. vivax isolates [25, 
36]. In addition to the ex  vivo chloroquine susceptibil-
ity assays, molecular markers, such as pvmdr1, have 
been used to examine chloroquine resistance in P. vivax 
isolates. The pvmdr1 gene encoding for an ATP bind-
ing cassette transporter, has been shown to modulate 
the responses of P. vivax to chloroquine and other anti-
malarial drugs [17, 28]. Therefore, the SNPs of pvmdr1 
were evaluated in isolates obtained from patients resid-
ing in the demilitarized zone. Compared to the pvmdr1 
gene of the reference P. vivax Sal I strain, SNPs at four 
loci of pvmdr1, one non-synonymous mutation (F1076L) 
and three synonymous SNPs (T529, E1233, and S1358; 
Table  2) were detected in the P. vivax isolated from 
patients. Mutant alleles at position 1076 (F1076L) were 
present in all isolates (100 %) obtained from samples col-
lected in 2011 and 2012. The number of SNPs at position 
529 (T529) and 1233 (E1233) was higher in the 2011 iso-
lates (T529, 57.1 %; E1233, 42.9 %) than in 2012 (T529, 
55.6 %; E1233, 33.3 %). Among these four SNPs, F1076L, 
T529, and E1233 have been reported previously [25]. 
The newly identified SNP was in codon 1358 (S1358). 
The S1358 SNP has been reported to be associated with 
the low chloroquine susceptibility of P. vivax in Thailand 
and Myanmar: this result could be considered to be an 
early sign of the increasing presence of the chloroquine-
resistant P. vivax strains in the Republic of Korea [25]. 
However, none of the analysed samples harboured a 
mutation at codon 976 (Y976F), which has been identi-
fied as a possible genetic marker of chloroquine resist-
ance in Southeast Asia and Papua New Guinea [28, 
37–39]. This data suggests that chloroquine-resistant 
P. vivax may not currently be prevalent in the Republic 
of Korea. The dN/dS ratios, the ratio of the rate of non-
synonymous substitutions to the rate of synonymous 
substitutions, were 0.935 (29/31) and 0.865 (32/37) for 
the isolates from 2011 and 2012, respectively. Although 
the dN/dS ratio of samples collected is below 1 and less 
than the dN/dS ratio of 2011 samples, these data cannot 
be concluded that the 2012 samples were under selective 
pressure.
Following the identification of SNPs, the multiple 
clone infection pattern, genetic diversity as well as inter- 
and intra-population differences between the pvmdr1 
groups was evaluated using 10 loci. Different alleles sizes 
observed in a single locus were classified as a multiplic-
ity of infection (MOI). The MOI referred to multiple 
clone infection. Multiple clone infection was observed 
in some of the microsatellite loci in 24 of the 55 isolates 
(49.1  %). Multiple clone infection occurred more fre-
quently in samples from 2011 (60.7  %, n =  17) than in 
those from 2012 (37.0 %, n = 10). The number of MOI 
loci per sample was also examined. The highest number 
of MOI loci per isolate was four, which we observed in a 
single isolate.
The major alleles of each locus were used for our pop-
ulation genetic analysis. As shown in Table  3, genetic 
diversity in P. vivax isolates from 2012 (A = 6.49 ± 0.49, 
Table 2 Distribution of  pvmdr1 mutations among  the 
P. vivax isolates obtained from the South Korean soldiers
Mutation Year % of mutated isolates (no. 
of isolates with mutation/total no. 
of isolates)
2011 2012
S513R (AGT/AGA) 0 (0/28) 0 (0/27)
T529 (ACA/ACG) 57.1 (16/28) 55.6 (15/27)
Y976F (TAC/TTC) 0 (0/28) 0 (0/27)
K997R (AAG/AGG) 0 (0/28) 0 (0/27)
F1076L (TTT/CTT) 100 (28/28) 100 (27/27)
E1233 (GAG/GAA) 42.9 (12/28) 33.3 (9/27)
S1358 (TCC/TCT) 0 (0/28) 3.7 (1/27)
K1393 N (AAG/AAC) 0 (0/28) 0 (0/27)
E1396 (GAG/GAA) 0 (0/28) 0 (0/27)
Table 3 Genetic diversity and  multilocus linkage disequi-
librium in P. vivax populations
A average number of the alleles ± SE, He average expected heterozygosity ± SE
Year A He IA
S
2011 5.23 ± 0.76 0.52 ± 0.29 0.028
2012 6.49 ± 0.49 0.72 ± 0.14 0.052
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He =  0.72 ±  0.14) was greater than in those from 2011 
(A = 5.23 ± 0.76, He = 0.52 ± 0.29). Moreover, the level 
of multilocus LD (IAS) was calculated using allelic data 
from all P. vivax isolates (Table 3). No significant multilo-
cus LD (IAS = 0.040, P > 0.05) was observed in the P. vivax 
population. Notably, there was greater multilocus LD in 
the 2012 population (IAS = 0.052) than in the 2011 popula-
tion (IAS = 0.028). The genetic diversity of P. vivax popula-
tion in Korea was greater than that reported by Iwagami 
et al. [26, 27]. Although the sample size (n) was small, the 
increased genetic diversity and decreased multilocus LD 
levels of recent P. vivax isolates observed appears to be 
a trend in Korea [26, 40]. The multilocus LD levels were 
very low (IAS = 0.028 in 2011; IAS = 0.052 in 2012), suggest-
ing a large possibility of outbreeding between different 
genotypes. These results are noteworthy since the num-
ber of vivax malaria cases is declining in Korea (1772 
cases in 2010, 826 cases in 2011, and 542 cases in 2012), 
which suggests that genetically new P. vivax isolates may 
emerge in the Republic of Korea every year. However, 
because the isolates exhibited few genetic differences, it 
would be difficult to conclude that the new P. vivax iso-
lates are from different high-risk areas of the Republic of 
Korea [41].
Microsatellite genotypes of the 55 isolates were deter-
mined based on a combination of the allelic data of the 10 
microsatellite loci, and 30 genotypes (G1–G30; Table 4) 
were identified. Three major genotypes, G12, G16, and 
G17 were identified. Seven (12.7  %) of the 55 isolates 
belonged to genotype G16, whereas five isolates each 
belonged to genotypes G12 and G17. The relationship 
between the 30 genotypes was determined by eBURST 
analysis with the following criterion: when two isolates 
shared more than two identical loci (out of the three loci), 
these were connected with a branch (Fig. 2). The eBURST 
analysis revealed two major groups, Group 1 and Group 
2. Group 1 contained 22 isolates (40.0 %), including the 
isolates of genotypes G12, G16, and G17. Group 2 con-
tained three isolates (5.5 %), including the isolates of gen-
otypes G5, G6, and G7. Five isolates of genotypes G4, G8, 
G29, and G30 were not included in the two major groups, 
nor were they connected to any other genotypes. Addi-
tionally, a single isolate with a new SNP at codon 1358 
(S1358) was classified as genotype G24 and was located 
at the end of the branch, indicating that this genotype 
is newly introduced into the Republic of Korea P. vivax 
population.
Conclusions
In conclusion, the pvmdr1 gene was analysed in samples 
collected from South Korean soldiers. The results showed 
that an isolate with a new SNP (S1358) of pvmdr1 has 
been introduced into the Korean P. vivax population and 
that the genetic diversity of the Korean P. vivax popula-
tion is likely to be greater in 2012 than in 2011. There-
fore, further continuous monitoring for the presence of 
Table 4 Thirty genotypes of the P. vivax population in the 
Republic of Korea












G10 1 1 2
G11 1 1




G16 4 3 7
G17 4 1 5
G18 3 3
G19 2 2











Total 28 27 55
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chloroquine resistant parasites using molecular markers is 
needed for the control of vivax malaria in the Republic of 
Korea.
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